GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2007

AMRI to Provide Discovery Services to Achaogen for its Biodefense Contract

  • Albany Molecular Research (AMRI) entered into a natural products-based drug discovery collaboration with Achaogen. The deal will support Achaogen’s $24.7 million Defense Threat Reduction Agency (DTRA) contract to develop therapies to treat anthrax and other biothreat agents.

    AMRI will use high-throughput screening to test samples from its natural product libraries for activity against targets of interest to Achaogen. AMRI will provide a full range of natural product-based discovery services, including fermentation, fractionation, and structure elucidation. If Achaogen chooses, AMRI may also supply follow-up services such as fermentation, optimization, scale-up, biocatalysis, and semi-synthetic chemistry.

    The agreement includes an upfront payment and opportunities for AMRI to receive milestone fees based on the achievement of specific development goals. Moreover, AMRI would receive royalties on net sales.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »